Literature DB >> 17400655

Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth.

Girish C Daginakatte1, David H Gutmann.   

Abstract

The tumor microenvironment is considered to play an important role in tumor formation and progression by providing both negative and positive signals that influence tumor cell growth. We and others have previously shown that brain tumor (glioma) formation in Nf1 genetically engineered mice requires a microenvironment composed of cells heterozygous for a targeted Nf1 mutation. Using NF1 as a model system to understand the contribution of the tumor microenvironment to glioma formation, we show that Nf1+/- brain microglia produce specific factors that promote Nf1-/- astrocyte growth in vitro and in vivo and identify hyaluronidase as one of these factors in both genetically engineered Nf1 mouse and human NF1-associated optic glioma. We further demonstrate that blocking hyaluronidase ameliorates the ability of Nf1+/- microglia to increase Nf1-/- astrocyte proliferation and that hyaluronidase increases Nf1-/- astrocyte proliferation in an MAPK-dependent fashion. Lastly, inhibiting microglia activation in genetically engineered Nf1 mice significantly reduces mouse optic glioma proliferation in vivo. Collectively, these studies identify Nf1+/- microglia as an important stromal cell type that promotes Nf1-/- astrocyte and optic glioma growth relevant to the pathogenesis of NF1-associated brain tumors and suggest that future brain therapies might be directed against paracrine factors produced by cells in the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400655     DOI: 10.1093/hmg/ddm059

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  104 in total

Review 1.  Brain extracellular space, hyaluronan, and the prevention of epileptic seizures.

Authors:  Katherine L Perkins; Amaia M Arranz; Yu Yamaguchi; Sabina Hrabetova
Journal:  Rev Neurosci       Date:  2017-11-27       Impact factor: 4.353

Review 2.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

3.  CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.

Authors:  Tao Sun; Scott M Gianino; Erin Jackson; David Piwnica-Worms; David H Gutmann; Joshua B Rubin
Journal:  J Neuroimmunol       Date:  2010-07-27       Impact factor: 3.478

4.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.

Authors:  Krishna P L Bhat; Veerakumar Balasubramaniyan; Brian Vaillant; Ravesanker Ezhilarasan; Howard Colman; Erik P Sulman; Kenneth Aldape; Karlijn Hummelink; Faith Hollingsworth; Khalida Wani; Lindsey Heathcock; Johanna D James; Lindsey D Goodman; Siobhan Conroy; Lihong Long; Nina Lelic; Suzhen Wang; Joy Gumin; Divya Raj; Yoshinori Kodama; Aditya Raghunathan; Adriana Olar; Kaushal Joshi; Christopher E Pelloski; Amy Heimberger; Se Hoon Kim; Daniel P Cahill; Ganesh Rao; Wilfred F A Den Dunnen; Hendrikus W G M Boddeke; Heidi S Phillips; Ichiro Nakano; Frederick F Lang
Journal:  Cancer Cell       Date:  2013-08-29       Impact factor: 31.743

Review 5.  Glioblastoma niches: from the concept to the phenotypical reality.

Authors:  Davide Schiffer; Marta Mellai; Enrica Bovio; Ilaria Bisogno; Cristina Casalone; Laura Annovazzi
Journal:  Neurol Sci       Date:  2018-05-08       Impact factor: 3.307

6.  Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.

Authors:  Carlos E Prada; Edwin Jousma; Tilat A Rizvi; Jianqiang Wu; R Scott Dunn; Debra A Mayes; Jose A Cancelas; Eva Dombi; Mi-Ok Kim; Brian L West; Gideon Bollag; Nancy Ratner
Journal:  Acta Neuropathol       Date:  2012-10-26       Impact factor: 17.088

Review 7.  Neurofibromatosis-related tumors: emerging biology and therapies.

Authors:  Matthias A Karajannis; Rosalie E Ferner
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

Review 8.  Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma.

Authors:  David H Gutmann
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 9.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

10.  Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation.

Authors:  Winnie W Pong; Samantha B Higer; Scott M Gianino; Ryan J Emnett; David H Gutmann
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.